Get started
Author

XingYa Li

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
2025 · Dan-Yun Ruan, Hao-Xiang Wu, et al. · Signal Transduction and Targeted Therapy · 31
PDF
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
2024 · Jia Zhong, Kailun Fei, et al. · Signal Transduction and Targeted Therapy · 31
PDF
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
2025 · Ying Cheng, Shuang Zhang, et al. · 癌症：英文版 · 28
PDF
A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
2022 · Di Geng, Qianqian Guo, et al. · Technology in Cancer Research & Treatment · 28
MiR-126 inhibits the invasion of gastric cancer cell in part by targeting Crk.
2014 · X Li, F Wang, et al. · PubMed · 25
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
2024 · Jun Zhao, Jian Fang, et al. · Journal of Clinical Oncology · 23
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.
2024 · Wenfeng Fang, Qiming Wang, et al. · Journal of Clinical Oncology · 21
9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
2024 · Jian Zhang, Rujiao Liu, et al. · Journal of Clinical Oncology · 21
Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer
2021 · D. Geng, Q. Guo, et al. · Clinical & Translational Oncology · 17
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
2025 · Shun Lu, Jie Wang, et al. · Journal of Clinical Oncology · 15
PDF
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
2025 · Li Zhang, Wenfeng Fang, et al. · Journal of Clinical Oncology · 14
PDF
Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.
2025 · Dingwei Ye, Shusuan Jiang, et al. · Journal of Clinical Oncology · 12
PDF
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.
2024 · Zhengbo Song, XingYa Li, et al. · Journal of Clinical Oncology · 11
PDF
Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.
2025 · Jian Li, Jing Huang, et al. · Journal of Clinical Oncology · 9
PDF
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
2025 · Yan Sun, Haochen Yang, et al. · Advanced Science · 8
Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
2025 · Wenfeng Fang, Qiming Wang, et al. · Journal of Clinical Oncology · 8
PDF
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
2025 · Jian Li, Zhenghang Wang, et al. · The Lancet. Gastroenterology & hepatology · 7
Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
2025 · Yuankai Shi, Longhua Sun, et al. · Journal of Clinical Oncology · 7
PDF
Downregulation of MACC1 expression enhances cisplatin sensitivity in SKOV-3/DDP cells
2015 · Z.M. Chen, H.R. Shi, et al. · Genetics and Molecular Research · 7
PDF
Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.
2025 · Ziming Li, Qiming Wang, et al. · Journal of Clinical Oncology · 6
OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
2024 · Q. Zhou, B. Gao, et al. · Journal of Thoracic Oncology · 5
PDF
Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study.
2024 · Anwen Xiong, XingYa Li, et al. · Journal of Clinical Oncology · 5
PDF
[Effect of the correlation between gut microbiota and folic acid in first-episode schizophrenia].
2021 · Y Miao, X Li, et al. · PubMed · 5
P2.10.12 Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant NSCLC: Final Results From the DESTINY-Lung05 Study
2025 · Y. Cheng, D. Li, et al. · Journal of Thoracic Oncology · 4
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.
2024 · Jin-Ji Yang, Yan Zhang, et al. · Journal of Clinical Oncology · 4
Works count: 57
Citation count: 389
H-index: 12
I10-index: 13
Year
Topic
Type